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Background: Subclinical myocardial involvement is common in systemic sclerosis (SSc) and associated with
poor prognosis. Early detection, particularly during follow-up, is important. Two-dimensional speckle tracking
echocardiography (STE) has already been shown to detect early left ventricular systolic impairment in SSc patients with
advanced disease. The aim of this study was to assess the ability of STE to diagnose changes in left ventricular function
in patients with SSc with preserved LV ejection fraction (LVEF) and normal pulmonary pressure over time.
Methods: This single-center pilot study included nineteen SSc patients without pulmonary hypertension and
preserved LVEF (55.2 ± 10.8 years, 13 women, mean modified Rodnan Skin Score of 8.2 ± 6.5, median disease duration
6 ± 4.5 years). We performed STE at baseline and after two years (mean 756.6 ± 8.8 days). Pulmonary hypertension was
ruled out in all patients by right heart catheterization (average mean PAP 17.7 ± 3.5 mmHg).
Results: The LVEF remained unchanged (63.3 ± 4.2% vs. 63.2 ± 5.0%, P = ns), but the global longitudinal peak systolic
strain of the left ventricle was significantly lower: baseline −22.0 ± 2.3% vs. follow-up −20.8 ± 2.1% (P = 0.04). The
regional analysis showed a heterogeneous distribution of segmental systolic dysfunction that did not match any
particular coronary artery distribution. In contrast, the LV diastolic function remained stable during follow-up.
Conclusion: STE might be a sensititive and valuable method to detect early LV systolic impairment in patients with SSc
and preserved LVEF during two years. Prospective evaluations are needed for prognostic implications of these changes.
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Clinical myocardial dysfunction in patients with systemic
sclerosis (SSc), an entity characterized by extensive fibrosis,
is recognized only in 15-25% [1,2]. In histological studies,
however, myocardial involvement is more common [3,4].
In the myocardium, fibrosis tends to be patchy but distrib-
uted throughout the myocardium in both ventricles [1].
Importantly, cardiac involvement is one of the leading
causes of disease-related death [2,5]. Fortunately, significant
advances in symptomatic organ-specific therapy have been
made during recent years [6]. Consequently, preclinical* Correspondence: sebastian.spethmann@charite.de
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article, unless otherwise stated.identification of myocardial manifestation is highly encour-
aged. At present, there is a lack of longitudinal evaluations
concerning the presence and development of functional
myocardial abnormalities. Echocardiography with newer
modalitites like 2D speckle tracking (STE) allow assess-
ment of myocardial deformation as a sensitive marker
for regional and global LV systolic function and have
already been analysed in SSc patients [7,8]. STE is a
semi-automatic algorithm that can be carried out quickly in
daily practise and is only minimally affected by inter- and
intraobserver variability [9]. Since STE uses only standard
2D images, analyses can be performed offline from even
already recorded examinations. These advantages let STE
appear as an attractive method particularly for serial echo-
cardiographic examinations.ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Clinical and biological characteristics of SSc patients
Systemic sclerosis (n = 19)
Age, (years) 55.2 ± 10.8
Sex (female), [n (%)] 13 (68.4%)
Disease duration, (years) 60 ± 4.5
Time of follow-up examination
after baseline examination, (days)
756.6 ± 8.8
Time of baseline echocardiography
between right heart catheter, (days)
6.0 ± 10.4
Body mass index (kg/m2) 24.0 ± 2.7
Arterial hypertension, [n (%)] 4 (21.1)
Smoker, [n (%)] 2 (10.5)
Raynaud’s syndrom, [n (%)] 8 (42.1)
Modified Rodnan Skin Score 8.2 ± 6.5
Anti-centromere antibodies, [n (%)] 4 (21.1)
Anti-Scl-70 antibodies, [n (%)] 7 (36.8)
Pulmonary fibrosis, [n (%)] 8 (42.1)
Impaired renal function, [n (%)] 2 (10.5)
Invasive measurements
Cardiac output, (l/min) 5.4 ± 0.7
Cardiac index, (l/min/m2) 3.0 ± 0.4
PAP systolic, (mmHg) 27.3 ± 4.9
PAP diastolic, (mmHg) 11.2 ± 3.1
PAP mean, (mmHg) 17.7 ± 3.5
PCWP mean, (mmHg) 10.1 ± 3.6
SVR, (dyn × sec × cm−5) 2203.3 ± 787.7
PVR, (dyn × sec × cm−5) 188.3 ± 98.6
Data are expressed as mean ± SD, except gender, hypertension, and except
disease duration and time of follow-up examination, which are expressed as
median ± SD. SSc, systemic sclerosis; PAP, pulmonary artery pressure; PCWP,
pulmonary capillary wedge pressure; SVR, systemic vascular resistance; PVR,
pulmonary vascular resistance.
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in LV function by STE in SSc patients with preserved
left ventricular ejection fraction (LVEF) and without
pulmonary hypertension over a duration of two years.
Methods
Study population
21 SSc patients without pulmonary hypertension, reduced
LVEF, or known coronary heart disease who were included
in the DETECT (Detection of PAH in SSc) study [10]
in our centre were screened. The study protocol was ap-
proved by the ethics committee of the Charité University
Hospital. All participants provided written consent. One
patient refused follow-up echocardiography and one had
to be excluded due to mitral valve sclerosis at baseline.
Therefore, nineteen patients with SSc according to the
American College of Rheumatology classification criteria
[11] (13 women, mean age 55.2 ± 10.8 years, range 33 to
74 years) with a median disease duration 6 ± 4.5 years
(range 2 to 17 years) and a mean modified Rodnan Skin
Score of 8.2 ± 6.5 were included into the study (Table 1).
All patients underwent echocardiography with STE at
baseline and 756.6 ± 8.8 days later to analyse global and
regional systolic LV function. Pulmonary hypertension was
ruled out in all patients by right heart catheterization [12]
(average mean PAP 17.7 ± 3.5 mmHg). Table 1 shows the
baseline characteristics in detail.
Echocardiography and conventional Doppler measurements
Standard transthoracic echocardiography was performed
in the left decubitus position using an ultrasound system
(Vivid 7, GE Medical Systems, Horton, Norway) with a
3.4-MHz multifrequency transducer. The LVEF was ob-
tained according to the recommendations of the ASE [13].
Left ventricular diastolic function was assessed using
pulsed-wave Doppler and pulsed-wave Doppler tissue
imaging (DTI) recordings on the basis of the recommen-
dations of the ASE. Transmitral flow was acquired to
obtain peak early (E) and atrial (A) flow velocities. We
used the average peak early diastolic (E’), peak late dia-
stolic (A’) and peak systolic velocity (S’) obtained from
the septal and lateral sides of the mitral annulus in the
fourchamber view with proper DTI settings. The E/E’
ratio was calculated to estimate LV filling pressures.
2D speckle tracking strain analysis
For assessment of longitudinal strain, we recorded stand-
ard 2D ultrasound images with a frame rate between
60 and 80 frames per second (fps) from the apical long
axis, and two- and four-chamber views. We stored these
recordings digitally for offline analysis (EchoPac PC,
Version 112.1.1, GE Vingmed, Horton, Norway) as previ-
ously described [14]. In short, we used a semi-automatic
algorithm for tracking the left ventricular myocardial wall,which was divided into 18 segments to obtain the global
peak systolic longitudinal strain.
Inter- and intraobserver variability analysis
Two echocardiographers, blinded to previously obtained
data, separately measured global PSS from 13 random
patients for interobserver variability analysis. Additionally,
an experienced observer calculated strain values twice
on two consecutive days for analysis of intraobserver
variability. We employed inter- and intraobserver vari-
ability to determine the interclass coefficient.
Statistics and figures
All results are expressed as mean ± standard deviation
(SD). Statistics were calculated using SPSS 21.0 (IBM
Corporation, Armonk, NY, USA). Wilcoxon-test was used
for the comparison of the paired observations. Interclass
Correlation Coefficient by Kolmogorov-Smirnov was used
to calculate inter- and interobserver variability. P values
Table 3 Left ventricular ejection fraction, pw DTI and
speckle tracking strain data
Baseline (n = 19) Follow-up (n = 19) p-value
LVEF, (%) 63.3 ± 4.2 63.2 ± 5.0 ns
Peak systolic
velocity (cm/s)




−22.0 ± 2.3 −20.8 ± 2.1 0.04
APLAX, (%) −21.5 ± 3.5 −20.3 ± 2.7 ns
4CH, (%) −22.1 ± 2.5 −19.8 ± 3.5 0.006
2CH, (%) −22.2 ± 2.7 −21.7 ± 2.6 ns
Data are expressed as mean ± SD. Pw DTI, pulsed wave doppler tissue imaging;
PSS, peak systolic strain; APLAX, apical long axis view; 4CH, apical four chamber




























P = 0.04 
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templates for Figure three were originally created by
Patrick J. Lynch and C. Carl Jaffe, MD and used with




Table 1 showed the clinical biological characteristics
of SSc patients as well as the results of right heart
catheterization. Importantly, all patients had normal
mean PAP values.
Conventional echocardiographic data
Conventional echocardiographic findings are presented
in Table 2. There were no differences between baseline and
follow-up examination regarding heart rate, left ventricular
volumes, aortic valve peak velocity and diastolic function.
(Table 2).
Speckle tracking strain data, DTI systolic velocities and
systolic left ventricular function
Table 3 shows global speckle tracking strain data and
systolic left ventricular function. LVEF at baseline was
normal in all patients and remained stable at follow-up
examination (63.3 ± 4.2% vs. 63.2 ± 5.0%, p = ns) (Figure 1).
In addition, the mean peak systolic velocities were also
unchanged (7.9 ± 1.7 vs. 7.9 ± 1.9, p = ns).
The mean global PSS value at follow-up was still in nor-
mal range, but significantly reduced compared to baseline
examination (baseline −22.0 ± 2.3% vs. follow-up −20.8 ±






Heart rate, (bmp) 71.2 ± 11.5 69.7 ± 8.8 ns
LVEDV, (ml) 62.9 ± 21.4 71.8 ± 28.5 ns
LVESV, (ml) 23.5 ± 9.3 27.0 ± 13.7 ns
LV mass index, (g/m2) 89.2 ± 14.3 93.8 ± 19.5 ns
Aortic valve peak
instantaneous velocity, (m/s)
1.3 ± 0.2 1.4 ± 0.3 ns
LV diastolic function
E, (m/s) 0.70 ± 0.16 0.70 ± 0.15 ns
A, (m/s) 0.69 ± 0.14 0.74 ± 0.14 ns
E/A 1.0 ± 0.3 1.0 ± 0.2 ns
E’, (cm/s) 8.5 ± 2.1 8.4 ± 2.3 ns
A’, (cm/s) 9.3 ± 1.9 9.4 ± 2.1 ns
E/E’ 8.4 ± 2.0 8.8 ± 2.8 ns
DT, (ms) 183.1 ± 50.8 176.9 ± 37.6 ns
Data are expressed as mean ± SD. LVEDV, left ventricular enddiastolic volume;
LVESV, left ventricular endsystolic volume; LV left ventricular; DT, deceleration
time.intraindividual course of the PSS. This was mainly influ-
enced by lower strain in the four-chamber view (−22.1 ±
2.5% vs. -19.8 ± 3.5%, p = 0.006) while there was only a

































Figure 1 Global longitudinal peak systolic strain (PSS) (A) and
left ventricular ejection fraction (B) in systemic sclerosis (SSc)



















Figure 2 Intraindividual course of the global longitudinal peak
systolic strain at baseline (Left Panel) and at follow-up (Right Panel).
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PSS in all segments but only the medial segments in the
four-chamber view were statistically significant (Table 4
and Figure 3).
Inter- and intraobserver variability
The intraobserver variability for the LV longitudinal strain
was 0.93 (CI 0.79-0.98). The interobserver variability for
the LV longitudinal strain was 0.90 (CI 0.57-0.99).
Discussion
Cardiac involvement in patients with SSc is associated
with a poor prognosis and is more frequent in SSc patients
than clinically suspected [15]. Therefore, a safe, cost-
effective, widely available and less observer-dependend




years (n = 19)
p-value
Basal segments, (%) −20.3 ± 3.0 −18.8 ± 2.8 0.053
APLAX, (%) −19.7 ± 4.0 −18.4 ± 3.9 0.286
4CH, (%) −19.7 ± 3.7 18.2 ± 3.3 0.076
2CH, (%) −22.4 ± 3.6 −20.2 ± 3.5 0.053
Medial segments, (%) −21.7 ± 2.3 −21.1 ± 2.6 0.243
APLAX, (%) −21.4 ± 3.1 −20.9 ± 3.0 0.687
4CH, (%) −21.9 ± 2.9 −20.6 ± 3.1 0.011
2CH, (%) −21.4 ± 2.8 −21.8 ± 3.5 0.687
Apical segments, (%) −23.8 ± 2.9 −22.2 ± 2.6 0.053
APLAX, (%) −22.6 ± 5.0 −21.6 ± 5.1 0.717
4CH, (%) −24.5 ± 4.0 −22.4 ± 4.4 0.113
2CH, (%) −23.7 ± 3.6 −22.9 ± 3.1 0.807
Data are expressed as mean ± SD. PSS, Peak systolic strain; APLAX, apical long
axis view; 4CH, apical four-chamber view; 2CH, apical two-chamber view.visits during the course of the disease. In our study, a
minor but significant decrease of the longitudinal LV
function was detected by STE in SSc patients with pre-
served LVEF over a duration of two years (Figure 1,
Figure 2, and Figure 4). In contrast, the diastolic function
remained stable. Importantly, the peak systolic strain
was within the range of normal both at baseline and at
follow-up. Accordingly, each examination considered
individually would not lead to a therapeutic or diagnos-
tic consequence. Only serial measurements displayed a
subclinical decrease in longitudinal function.
Although it has been shown that STE-derived strain
is a sensitive marker for the detection of clinical and
subclinical myocardial left heart dysfunction in a variety of
pathologies, even during follow-up [16], to our knowledge
the present study is the first to use STE in patients with
SSc as a follow-up tool for daily practice.
In clinical routine, assessment of global systolic function
is usually based on the LVEF. This parameter, however, is
insufficient in describing the complex myocardial motion.
Moreover, LVEF mainly depends on the radial and cir-
cumferential deformation caused by less sensitive mid-
myocardial and epicardial fibres. In contrast, longitudinal
function is predominantly influenced by subendocardial
fibres which are most susceptible to evident myocardial
damage [17] with preserved LVEF. In addition, despite clear
recommendations [13], LVEF is often visually assessed by
“eye-balling” with relevant inter- and intraobser variability
[18] which inhibits its use for subtle assessment during
follow-up. In contrast, 2D speckle tracking derived longi-
tudinal strain is a semiautomatic method that is only
minimally affected by inter- and intraobserver variability
[9] with with a low test–re-test variability [19] and it can
be performed offline from recorded examinations using
standard 2D images.
Our regional analysis showed a heterogeneous distribu-
tion of declining systolic dysfunction that did not match
any particular coronary artery distribution. Histologic
studies diagnosed a patchy myocardial fibrosis in up to
80% of patients with SSc [4]. This pattern is well in line
with our observation of a dissiminated subclinical decline
in regional longitudinal deformation which accordingly
may be caused by a slow progression of myocardial fibrosis
[3,4]. Due to the disseminated pattern of changes in longi-
tudinal function we emphasize the use of global indices for
tracking the systolic function in serial measurements.
No patients had to be excluded due to poor image
quality. This indicates an acceptable feasibility of echo-
cardiographic assessment of LV function by speckle track-
ing in SSc patients.
Limitations
First, our study was designed as a retrospective, pilot


















Baseline Follow up 
Figure 3 Colour-coding of the average regional longitudinal peak systolic strain in patients with SSC at baseline (Left Panel) and at
follow-up (Right Panel). A: The apical long axis view. B: The four chamber view. C: The two chamber view.
A
Baseline Follow up 
B
Figure 4 Bull’s-eye diagram of a patient with SSc at baseline and at follow-up. Left Panel (A): a global longitudinal peak systolic strain
of -21.6% at baseline. Right Panel (B): a global longitudinal peak systolic strain of -16.1% at follow-up (Right Panel, B).
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prognostic implications of these mild changes in LV func-
tion. Additional prospective studies are needed to clarify
whether systematic echocardiographic surveillance should
be recommended in order to improve the prognosis in
this population. Second, we did not track healthy controls
over time. Therefore, we cannot completely exclude other
variables that might have influenced our results in patients
with SSc, e.g. like ageing. Nevertheless, we do not believe
in aging effects since it takes decades for longitudinal
function to decrease [20]. Third, myocardial fibrosis as
a potential reason for a decline in longitudinal function
was not assessed by cardiac magnetic resonance imaging
(MRI) or myocardial biopsies. Fourth, our study included
only long-term scleroderma patients with a median
time of 6 years from diagnosis. Therefore, 7 (36.8%) of
the included patients had already received potentially
cardiotoxic disease-modifying agents (azathioprine, metho-
trexate or cyclosporine A). Accordingly, we cannot rule
out that the reduced longitudinal strain in SSc patients
was, at least in part, due to side effects of the medical
therapy. Finally, the DETECT study enrolled SSc patients
with a reduced diffusing capacity of the lung for carbon
monoxide leading to a potential selection bias. Therefore,
our results should be transferred with caution to SSc
patients without pulmonary involvement.
Conclusion
STE detect subtle changes of systolic LV function in
patients with SSc and preserved LVEF and normal pul-
monary pressure after two years. Since cardiac involvement
is common, our results may be explained by a progression
of subclinical myocardial fibrosis. STE might be a sensiti-
tive and valuable method for follow-up of SSc patients, but
prospective evaluations are needed for prognostic implica-
tions of these changes.
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